Skip to main content
NWBO
OTC Life Sciences

NW Bio Registers $4.9M Yorkville Convertible Note at $0.16/Share

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.164
Mkt Cap
$276.844M
52W Low
$0.141
52W High
$0.368
52W Position info
16% above low
Off High info
55% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

NWBO sits 16% above its 52-week low of $0.141 on light trading volume (0.4× avg).

Summary

NW Bio registers a new $4.9M convertible note with Yorkville, issuing shares at $0.16 and warrants at $0.205 — dilutive survival financing for a cash-strapped biotech. The company also entered a $50 million standby equity subscription agreement with Yorkville, usable after the note is repaid or converted, and cancelled the prior standby agreement.

Updated with an SEC 8-K filing · What changed

Updates

  1. · SEC 8-K — The company also entered a $50 million standby equity subscription agreement with Yorkville, usable after the note is repaid or converted, and cancelled the prior standby agreement. Yorkville received a warrant to purchase up to $2 million of shares at $0.205 per share.


Key Events · Financing and Capital Events · NWBO

  • New · · SEC 8-K

    $50M Standby Equity Agreement with Yorkville

    The company also entered a $50 million standby equity subscription agreement with Yorkville, usable after the note is repaid or converted, and cancelled the prior standby agreement. Yorkville received a warrant to purchase up to $2 million of shares at $0.205 per share.

  • $4.9M Convertible Note with Yorkville

    A $4.9 million convertible promissory note was entered into with YA II PN, Ltd. (Yorkville) on July 29, 2026. The note matures in 12 months, carries a 5% OID, no interest, and converts at a small discount to market.

  • 40.3M Shares Registered for Conversion & Warrants

    The registration covers 30,625,000 shares for note conversion at an assumed $0.16 per share, and 9,700,000 warrant shares exercisable at $0.205 per share for three years. Actual conversion shares may vary with market price.

  • Net Proceeds of $4.655M

    After original issue discount and fees, the company receives approximately $4.655 million, intended for working capital, manufacturing expansion, and clinical trials.

  • Dilution and Overhang

    The 40.3 million shares represent about 2.4% of the current 1.69 billion outstanding shares, but the note's variable conversion price and warrants add ongoing dilution risk. The company already has a going-concern warning and negative tangible book value.


Analysis · NWBO · Life Sciences

On July 29, 2026, Northwest Biotherapeutics entered a $4.9 million convertible note with YA II PN, Ltd. (Yorkville) and is registering 40.3 million shares to cover potential conversions and warrants. The note converts at a small discount to market, with an assumed price of $0.16 — right at the current $0.164 stock price. Net proceeds are $4.655 million after fees. This is dilutive survival financing for a company already under a going-concern warning and burning cash. The deal includes 9.7 million warrant shares at $0.205, adding further overhang. While the cash extends the runway, the structure — a convertible note with a discount and warrants — is typical of distressed biotech funding and will pressure the stock. The company also entered a $50 million standby equity subscription agreement with Yorkville, usable after the note is repaid or converted, and cancelled the prior standby agreement. Yorkville received a warrant to purchase up to $2 million of shares at $0.205 per share.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NWBO was trading at $0.16 on OTC in the Life Sciences sector, with a market capitalization of approximately $276.8M. The 52-week trading range was $0.14 to $0.37. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NWBO - Latest Insights

NWBO
Nov 13, 2026, 4:36 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.1565
Real-time Price: $0.139 info
Change: -$0.0175 (-11%) info
Market Cap: $229.214M info
NWBO
Oct 30, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.170
Real-time Price: $0.139 info
Change: -$0.031 (-18%) info
Market Cap: $229.214M info
NWBO
Oct 08, 2026, 5:15 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.148
Real-time Price: $0.139 info
Change: -$0.0090 (-6%) info
Market Cap: $229.214M info
NWBO
Aug 14, 2026, 4:17 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.192
Real-time Price: $0.139 info
Change: -$0.053 (-28%) info
Market Cap: $229.214M info
NWBO
Jul 31, 2026, 5:17 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.164
Real-time Price: $0.139 info
Change: -$0.025 (-15%) info
Market Cap: $229.214M info